| FIALA, Ondřej, Miloš PEŠEK, Jindřich FÍNEK, Lucie BENEŠOVÁ, Zbyněk BORTLÍČEK a Marek MINÁRIK. Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence. Anticancer Research. Athens: The International Institute of Anticancer Research, 2013, roč. 33, č. 8, s. 3397-3402. ISSN 0250-7005. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1121101,
author = {Fiala, Ondřej and Pešek, Miloš and Fínek, Jindřich and Benešová, Lucie and Bortlíček, Zbyněk and Minárik, Marek},
article_location = {Athens},
article_number = {8},
keywords = {Pemetrexed; erlotinib; adenocarcinoma; NSCLC; second-line; third-line; sequence},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence},
volume = {33},
year = {2013}
}
TY - JOUR
ID - 1121101
AU - Fiala, Ondřej - Pešek, Miloš - Fínek, Jindřich - Benešová, Lucie - Bortlíček, Zbyněk - Minárik, Marek
PY - 2013
TI - Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence
JF - Anticancer Research
VL - 33
IS - 8
SP - 3397-3402
EP - 3397-3402
PB - The International Institute of Anticancer Research
SN - 02507005
KW - Pemetrexed
KW - erlotinib
KW - adenocarcinoma
KW - NSCLC
KW - second-line
KW - third-line
KW - sequence
N2 - Background: Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). Patients and Methods: We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. Results: The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). Conclusion: The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence.
ER -
FIALA, Ondřej, Miloš PEŠEK, Jindřich FÍNEK, Lucie BENEŠOVÁ, Zbyněk BORTLÍČEK a Marek MINÁRIK. Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2013, roč.~33, č.~8, s.~3397-3402. ISSN~0250-7005.
|
